These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 20834039

  • 1. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
    Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5063 Study Group.
    Mult Scler; 2010 Nov; 16(11):1360-6. PubMed ID: 20834039
    [Abstract] [Full Text] [Related]

  • 2. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5062 Study Group.
    Lancet; 2008 Jun 21; 371(9630):2085-92. PubMed ID: 18572078
    [Abstract] [Full Text] [Related]

  • 3. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 4. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, ALLEGRO Study Group.
    N Engl J Med; 2012 Mar 15; 366(11):1000-9. PubMed ID: 22417253
    [Abstract] [Full Text] [Related]

  • 5. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J.
    Expert Opin Investig Drugs; 2009 Jul 15; 18(7):985-9. PubMed ID: 19527103
    [Abstract] [Full Text] [Related]

  • 6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 7. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 15; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 8. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 15; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 9. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
    Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.
    J Neuroinflammation; 2017 Aug 31; 14(1):172. PubMed ID: 28859672
    [Abstract] [Full Text] [Related]

  • 10. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1098-107. PubMed ID: 22992073
    [Abstract] [Full Text] [Related]

  • 11. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

  • 12. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 13. Oral laquinimod treatment in multiple sclerosis.
    Fernández O.
    Neurologia; 2011 Mar 04; 26(2):111-7. PubMed ID: 21163185
    [Abstract] [Full Text] [Related]

  • 14. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
    Hainke U, Thomas K, Ziemssen T.
    Expert Opin Drug Metab Toxicol; 2016 Jun 04; 12(6):701-9. PubMed ID: 27089834
    [Abstract] [Full Text] [Related]

  • 15. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
    Mult Scler; 2022 Apr 04; 28(4):608-619. PubMed ID: 34378456
    [Abstract] [Full Text] [Related]

  • 16. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R, MN166-001 Investigators.
    Neurology; 2010 Mar 30; 74(13):1033-40. PubMed ID: 20200338
    [Abstract] [Full Text] [Related]

  • 17. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 30; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 18. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
    Constantinescu SE, Constantinescu CS.
    Expert Rev Clin Pharmacol; 2016 Apr 30; 9(1):49-57. PubMed ID: 26536299
    [Abstract] [Full Text] [Related]

  • 19. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
    Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, Lambert E, Hartung HP.
    Mult Scler Relat Disord; 2016 Sep 30; 9():95-100. PubMed ID: 27645352
    [Abstract] [Full Text] [Related]

  • 20. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 30; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.